4-[(2-fluorophenyl)methoxy]pyridin-2(1H)-one | 1335195-54-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-[(2-fluorophenyl)methoxy]pyridin-2(1H)-one
• 英文别名: 4-(fluorobenzyl)oxy-2(1H)-pyridone；4-[(2-fluorophenyl)methoxy]-1H-pyridin-2-one
• CAS: 1335195-54-4
• 化学式: C₁₂H₁₀FNO₂
• 分子量: 219.215
• InChiKey: XHSBXTOCKPYGCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(2-fluorophenyl)methoxy]pyridin-2(1H)-one 、 tert-butyl 7-bromo-3,4-dihydrobenzofuro[3,2-c]pyridine-2(1H)-carboxylate 在 copper(l) iodide 、 caesium carbonate 、 (1R,2R)-(-)-N,N'-二甲基-1,2-环己二胺 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  苯并呋喃-吡啶和吡嗪-吲哚衍生物作为 MCHR1 拮抗剂的 hERG 优化

  摘要：

  更健康的心脏：已鉴定出含有苯并呋喃-吡啶或吡嗪-吲哚支架的黑色素浓缩激素受体 1 (MCHR1) 拮抗剂。微调亲脂性和胺碱度使化合物17和23 g的 hERG 抑制和代谢清除均降低。

  DOI：

  10.1002/cmdc.202100707
• 作为产物：
  描述：

  2-氟苄醇 在 苄基三乙基氯化铵 、 乙酸酐 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 16.0h， 生成 4-[(2-fluorophenyl)methoxy]pyridin-2(1H)-one
  参考文献：
  名称：

  苯并呋喃-吡啶和吡嗪-吲哚衍生物作为 MCHR1 拮抗剂的 hERG 优化

  摘要：

  更健康的心脏：已鉴定出含有苯并呋喃-吡啶或吡嗪-吲哚支架的黑色素浓缩激素受体 1 (MCHR1) 拮抗剂。微调亲脂性和胺碱度使化合物17和23 g的 hERG 抑制和代谢清除均降低。

  DOI：

  10.1002/cmdc.202100707

文献信息

• Bicyclic aromatic substituted pyridone derivative
  申请人：Sakuraba Shunji

  公开号：US20090264426A1

  公开（公告）日：2009-10-22

  Disclosed is a compound represented by the formula (I): Wherein R 1 and R 2 independently represent a hydrogen atom, a lower alkyl group or the like; X 1 , X 2 and X 3 independently represent a methine group or a nitrogen atom; Y 1 and Y 3 independently represent a single bond, —O— or the like; Y 2 represents a lower alkylene group or the like; W1 to W4 independently represent a single bond, a methylene group or the like; L represents a single bond, a methylene group or the like; Z 1 and Z 2 independently represent a single bond, a C 1-4 alkylene group or the like; Ar 1 represents an aromatic carbocyclic ring or the like; and Ar 2 represents a bicyclic aromatic carbocyclic ring or the like. The compound is useful as a pharmaceutical for a central disease, a cardiovascular disease or a metabolic disease.

  本发明揭示了一种化合物，其化学式为（I）：其中R1和R2分别代表氢原子、低碳烷基或类似物；X1、X2和X3分别代表亚甲基基团或氮原子；Y1和Y3分别代表单键、—O—或类似物；Y2代表低碳烷基基团或类似物；W1至W4独立地代表单键、亚甲基基团或类似物；L代表单键、亚甲基基团或类似物；Z1和Z2独立地代表单键、C1-4烷基基团或类似物；Ar1代表芳香环烷基环或类似物；Ar2代表双环芳香环烷基环或类似物。该化合物可用作治疗中枢疾病、心血管疾病或代谢性疾病的药物。
• BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1939194A1

  公开（公告）日：2008-07-02

  Disclosed is a compound represented by the formula (I): Wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like; X1 , X2 and X3 independently represent a methine group or a nitrogen atom; Y1 and Y3 independently represent a single bond, -O- or the like; Y2 represents a lower alkylene group or the like; W1 to W4 independently represent a single bond, a methylene group or the like; L represents a single bond, a methylene group or the like; Z1 and Z2 independently represent a single bond, a C1-4 alkylene group or the like; Ar1 represents an aromatic carbocyclic ring or the like; and Ar2 represents a bicyclic aromatic carbocyclic ring or the like. The compound is useful as a pharmaceutical for a central disease, a cardiovascular disease or a metabolic disease.

  本发明公开了一种由式 (I) 表示的化合物： 其中 R1 和 R2 独立地代表氢原子、低级烷基或类似物；X1、X2 和 X3 独立地代表甲基或氮原子；Y1 和 Y3 独立地代表单键、-O- 或类似物；Y2 代表低级亚烷基或类似物；W1 至 W4 独立地代表单键、亚甲基或类似物；L 代表单键、亚甲基或类似物；Z1 和 Z2 独立地代表单键、C1-4 亚烷基或类似物；Ar1 代表芳香碳环或类似物；Ar2 代表双环芳香碳环或类似物。该化合物可用作治疗中枢疾病、心血管疾病或代谢疾病的药物。
• Strategies to lower the Pgp efflux liability in a series of potent indole azetidine MCHR1 antagonists
  作者：Kai Lu、Yu Jiang、Bin Chen、Eman M. Eldemenky、Gil Ma、Mathivanan Packiarajan、Gamini Chandrasena、Andrew D. White、Kenneth A. Jones、Boshan Li、Sang-Phyo Hong

  DOI：10.1016/j.bmcl.2011.07.020

  日期：2011.9

  A series of potent indolyl azetidine rMCHR1 antagonists were found to show poor CNS penetration due to Pgp efflux. We envisioned a strategy which included: lowering basicity; changing the conformational flexibility motif; and removal of a hydrogen bond donor, in an attempt to optimize this property while maintaining target receptor efficacy. This work resulted in mitigation of Pgp efflux, and led us to identify 1-dihydroindolyl azetidine derivatives with CNS penetration and excellent rMCHR1 binding affinity. (C) 2011 Elsevier Ltd. All rights reserved.
• INDOLE DERIVATIVES
  申请人：Richter Gedeon Nyrt.

  公开号：EP3286193A1

  公开（公告）日：2018-02-28
• [EN] INDOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'INDOLE
  申请人：RICHTER GEDEON NYRT

  公开号：WO2016166684A1

  公开（公告）日：2016-10-20

  The present invention relates to compounds of the general form (I). The present invention relates to new substituted diazepino-indole derivatives of the general formula (I), and to pharmaceutically acceptable salts thereof, as well as to pharmaceutical compositions comprising such compounds, to new intermediate thereof, as well as to the use of such compounds in treatment or prevention of disorders associated with melanin-concentrating hormone receptor 1 activity.